• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

PHARMING GROUP (PHARM)

PHARMING GROUP
Sell: €0.772|Buy: €0.78|Change: 0.01 (0.65%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib),a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Address



NLD

Telephone

+31 071 5247431

Website

https://www.pharming.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Pharming Group Annual Report for 20252026-04-03T00:00:00
Pharming Group Fourth Quarter Earnings Conference Call for 20252026-03-13T20:30:00
Pharming Group Fourth Quarter Earnings Results for 20252026-03-13T00:00:00
Pharming Group Third Quarter Earnings Conference Call for 20252025-10-24T07:30:00
Pharming Group Third Quarter Earnings Results for 20252025-10-24T00:00:00
Pharming Group Second Quarter Earnings Results for 20252025-08-01T00:00:00
Pharming Group Second Quarter Earnings Conference Call for 20252025-08-01T00:00:00
Pharming Group Annual General Meeting for 20252025-05-21T14:30:00
Pharming Group First Quarter Earnings Conference Call for 20252025-05-08T07:30:00
Pharming Group First Quarter Earnings Results for 20252025-05-08T00:00:00

Previous key dates

NameKey Date
Pharming Group Annual General Meeting for 20252025-05-21T14:30:00
Pharming Group First Quarter Earnings Conference Call for 20252025-05-08T07:30:00
Pharming Group First Quarter Earnings Results for 20252025-05-08T00:00:00
Pharming Group Annual Report for 20242025-04-03T00:00:00
37th Annual Roth Conference2025-03-17T13:30:00
Pharming Group Fourth Quarter Earnings Conference Call for 20242025-03-13T20:30:00
Pharming Group Fourth Quarter Earnings Result for 20242025-03-13T00:00:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference2025-02-12T08:40:00
Pharming Group Conference Call2024-12-16T14:00:00
Pharming Group to participate in Jefferies London Healthcare Conference 20242024-11-20T08:00:00
Pharming Group Third Quarter Earnings Conference Call for 20242024-10-24T07:30:00
Pharming Group Third Quarter Earnings Result for 20242024-10-24T00:00:00
H.C. Wainwright 26th Annual Global Investment Conference2024-09-09T10:30:00
2024 Wells Fargo Healthcare Conference2024-09-06T08:45:00
Pharming Group Second Quarter Earnings Result for 20242024-08-01T00:00:00
Pharming Group Second Quarter Earnings Conference Call for 20242024-08-01T00:00:00
Oppenheimer 2024 Montauk Life Sciences Summit2024-06-26T00:00:00
Oppenheimer Novel Targets in Immunology Summit2024-06-24T13:30:00
Jefferies Healthcare Conference2024-06-05T10:30:00
Pharming Group Annual General Meeting for 20242024-05-21T14:30:00
Pharming Group First Quarter Earnings Conference Call for 20242024-05-08T07:30:00
Pharming Group First Quarter Earnings Result for 20242024-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.